Advanced search

Online first
Guidelines / Expert consensus
Published online: 2024-12-27

open access

View PDF Download PDF file
Page views 127
Article views/downloads 91
Get Citation

Connect on Social Media

Connect on Social Media

Optimization of systemic treatment in patients with bladder, ureter, and renal pelvis cancer — expert opinion of the Polish Society of Clinical Oncology

Piotr Wysocki1, Maciej Krzakowski2, Łukasz Kwinta1, Jakub Kucharz3, Iwona Skoneczna45, Paweł Wiechno3
DOI: 10.5603/ocp.102532

Abstract

Not available

Article available in PDF format

View PDF Download PDF file

References

  1. Gakis G, Efstathiou J, Lerner SP, et al. International Consultation on Urologic Disease-European Association of Urology Consultation on Bladder Cancer 2012. ICUD-EAU International Consultation on Bladder Cancer 2012: Radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder. Eur Urol. 2013; 63(1): 45–57.
    CrossRefPubMed
  2. Rödel C, Grabenbauer GG, Kühn R, et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol. 2002; 20(14): 3061–3071.
    CrossRefPubMed
  3. von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005; 23(21): 4602–4608.
    CrossRefPubMed
  4. Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003; 349(9): 859–866.
    CrossRefPubMed
  5. Bellmunt J, Hussain M, Gschwend JE, et al. IMvigor010 Study Group. Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2021; 22(4): 525–537.
    CrossRefPubMed
  6. Sherif A, Rintala E, Mestad O, et al. Nordic Urothelial Cancer Group. Neoadjuvant cisplatin-methotrexate chemotherapy for invasive bladder cancer -- Nordic cystectomy trial 2. Scand J Urol Nephrol. 2002; 36(6): 419–425.
    CrossRefPubMed
  7. Sengeløv L, von der Maase H, Lundbeck F, et al. Neoadjuvant chemotherapy with cisplatin and methotrexate in patients with muscle-invasive bladder tumours. Acta Oncol. 2002; 41(5): 447–456.
    CrossRefPubMed
  8. Martinez-Piñeiro JA, Gonzalez Martin M, Arocena F, et al. Neoadjuvant cisplatin chemotherapy before radical cystectomy in invasive transitional cell carcinoma of the bladder: a prospective randomized phase III study. J Urol. 1995; 153(3 Pt 2): 964–973.
    PubMed
  9. Yin M, Joshi M, Meijer RP, et al. Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Systematic Review and Two-Step Meta-Analysis. Oncologist. 2016; 21(6): 708–715.
    CrossRefPubMed
  10. Bamias A, Dafni U, Karadimou A, et al. Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03). Ann Oncol. 2013; 24(4): 1011–1017.
    CrossRefPubMed
  11. Anari F, O'Neill J, Choi W, et al. Neoadjuvant Dose-dense Gemcitabine and Cisplatin in Muscle-invasive Bladder Cancer: Results of a Phase 2 Trial. Eur Urol Oncol. 2018; 1(1): 54–60.
    CrossRefPubMed
  12. Pfister C, Gravis G, Fléchon A, et al. Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses. Eur Urol. 2021; 79(2): 214–221.
    CrossRefPubMed
  13. Pfister C, Gravis G, Flechon A, et al. Multicenter randomized phase III trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as perioperative chemotherapy for muscle-invasive bladder cancer (MIBC): Overall survival (OS) data at 5 years in the GETUG/AFU V05 VESPER trial. J Clin Oncol. 2023; 41(17_suppl): LBA4507–LBA4507.
    CrossRef
  14. Klein C, Mebroukine S, Madéry M, et al. Myeloid-Derived Suppressor Cells in Bladder Cancer: An Emerging Target. Cells. 2024; 13(21).
    CrossRefPubMed
  15. Vetterlein MW, Wankowicz SAM, Seisen T, et al. Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology. Cancer. 2017; 123(22): 4346–4355.
    CrossRefPubMed
  16. Matin SF, Margulis V, Kamat A, et al. Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract transitional cell carcinoma. Cancer. 2010; 116(13): 3127–3134.
    CrossRefPubMed
  17. Liao RS, Gupta M, Schwen ZR, et al. Comparison of Pathological Stage in Patients Treated with and without Neoadjuvant Chemotherapy for High Risk Upper Tract Urothelial Carcinoma. J Urol. 2018; 200(1): 68–73.
    CrossRefPubMed
  18. Meng X, Chao B, Vijay V, et al. High Response Rates to Neoadjuvant Chemotherapy in High-Grade Upper Tract Urothelial Carcinoma. Urology. 2019; 129: 146–152.
    CrossRefPubMed
  19. Kubota Y, Hatakeyama S, Tanaka T, et al. Oncological outcomes of neoadjuvant chemotherapy in patients with locally advanced upper tract urothelial carcinoma: a multicenter study. Oncotarget. 2017; 8(60): 101500–101508.
    CrossRefPubMed
  20. Hosogoe S, Hatakeyama S, Kusaka A, et al. Platinum-based Neoadjuvant Chemotherapy Improves Oncological Outcomes in Patients with Locally Advanced Upper Tract Urothelial Carcinoma. Eur Urol Focus. 2018; 4(6): 946–953.
    CrossRefPubMed
  21. Porten S, Siefker-Radtke AO, Xiao L, et al. Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma. Cancer. 2014; 120(12): 1794–1799.
    CrossRefPubMed
  22. Margulis V, Puligandla M, Trabulsi EJ, et al. Collaborators. Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery in Patients with High Grade Upper Tract Urothelial Carcinoma. J Urol. 2020; 203(4): 690–698.
    CrossRefPubMed
  23. Coleman J, Yip W, Wong N, et al. Multicenter Phase II Clinical Trial of Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy for Patients With High-Grade Upper Tract Urothelial Carcinoma. J Clin Oncol. 2023; 41(8): 1618–1625.
    CrossRefPubMed
  24. Jatwani K, Roy A, Attwood K, et al. Neoadjuvant chemotherapy (NAC) versus adjuvant chemotherapy (AC) in patients with clinically node-positive upper tract urothelial cancer (UTUC) who underwent radical nephroureterectomy (RNU). J Clin Oncol. 2023; 41(6_suppl): 486–486.
    CrossRef
  25. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Bladder Cancer Version 3.2021. https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf (22.04.2021).
  26. Horwich A, Babjuk M, Bellmunt J, et al. EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees†. Ann Oncol. 2019; 30(11): 1697–1727.
    CrossRefPubMed
  27. Sternberg CN, Skoneczna I, Kerst JM, et al. European Organisation for Research and Treatment of Cancer Genito-Urinary Cancers Group, Groupe d'Etude des Tumeurs Urogénitales, National Cancer Research Institute Bladder Cancer Study Group, National Cancer Institute of Canada Clinical Trials Group, German Association of Urologic Oncology. Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial. Lancet Oncol. 2015; 16(1): 76–86.
    CrossRefPubMed
  28. Burdett S, Fisher D, Vale C, et al. Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Controlled Trials. Eur Urol. 2022; 81(1): 50–61.
    CrossRefPubMed
  29. Bellmunt J, Orsola A, Leow JJ, et al. ESMO Guidelines Working Group. Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014; 25 Suppl 3: iii40–iii48.
    CrossRefPubMed
  30. ESMO Guidelines Committee. eUpdate – Bladder Cancer Treatment Recommendations Published: 22 August 2019.
  31. https://uroweb.org/guideline/bladder-cancer-muscle-invasive-and-metastatic/#7.
  32. Birtle A, Johnson M, Chester J, et al. Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial. Lancet. 2020; 395(10232): 1268–1277.
    CrossRefPubMed
  33. Bellmunt J, Hussain M, Gschwend JE, et al. IMvigor010 Study Group. Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2021; 22(4): 525–537.
    CrossRefPubMed
  34. Bajorin D, Witjes J, Gschwend J, et al. Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma. N Engl J Med. 2021; 384(22): 2102–2114.
    CrossRefPubMed
  35. Brown G, Khilfeh I, Du S, et al. Prostate-specific antigen (PSA) response among patients with metastatic castration-sensitive prostate cancer (mCSPC) initiated on apalutamide (APA) or abiraterone acetate (ABI) in real-world urology practices. J Clin Oncol. 2024; 42(4_suppl): 53–53.
    CrossRef
  36. Bianchi M, Roghmann F, Becker A, et al. Age-stratified distribution of metastatic sites in bladder cancer: A population-based analysis. Can Urol Assoc J. 2014; 8(3-4): E148–E158.
    CrossRefPubMed
  37. Galsky MD, Krege S, Lin CC, et al. Cisplatin-based combination chemotherapy in septuagenarians with metastatic urothelial cancer. Urol Oncol. 2014; 32(1): 30.e15–30.e21.
    CrossRefPubMed
  38. Abuhelwa AY, Bellmunt J, Kichenadasse G, et al. Enhanced Bellmunt Risk Score for Survival Prediction in Urothelial Carcinoma Treated With Immunotherapy. Clin Genitourin Cancer. 2022; 20(2): 132–138.
    CrossRefPubMed
  39. Powles T, Valderrama B, Gupta S, et al. Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer. N Engl J Med. 2024; 390(10): 875–888.
    CrossRefPubMed
  40. von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000; 18(17): 3068–3077.
    CrossRefPubMed
  41. Bamias A, Dafni U, Karadimou A, et al. Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03). Ann Oncol. 2013; 24(4): 1011–1017.
    CrossRefPubMed
  42. Sternberg CN, de Mulder P, Schornagel JH, et al. EORTC Genito-Urinary Cancer Group. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer. 2006; 42(1): 50–54.
    CrossRefPubMed
  43. Hussain SA, Stocken DD, Riley P, et al. A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer. Br J Cancer. 2004; 91(5): 844–849.
    CrossRefPubMed
  44. Hussain SA, Palmer DH, Lloyd B, et al. A study of split-dose cisplatin-based neo-adjuvant chemotherapy in muscle-invasive bladder cancer. Oncol Lett. 2012; 3(4): 855–859.
    CrossRefPubMed
  45. Heijden Mv, Sonpavde G, Powles T, et al. Nivolumab plus Gemcitabine–Cisplatin in Advanced Urothelial Carcinoma. N Engl J Med. 2023; 389(19): 1778–1789.
    CrossRefPubMed
  46. Galsky M, Sonpavde G, Powles T, et al. Characterization of complete responders to nivolumab + gemcitabine-cisplatin vs gemcitabine-cisplatin alone and patients with lymph node–only metastatic urothelial carcinoma from the CheckMate 901 trial. J Clin Oncol. 2024; 42(16_suppl): 4509–4509.
    CrossRef
  47. Barkan G, Wojcik E, Nayar R, et al. The Paris System for Reporting Urinary Cytology: The Quest to Develop a Standardized Terminology. Adv Anat Pathol. 2016; 23(4): 193–201.
    CrossRef
  48. Powles T, Park SeH, Voog E, et al. Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. N Engl J Med. 2020; 383(13): 1218–1230.
    CrossRefPubMed
  49. De Santis M, Bellmunt J, Mead G, et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol. 2012; 30(2): 191–199.
    CrossRefPubMed
  50. Galsky MD, Chen GJ, Oh WK, et al. Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma. Ann Oncol. 2012; 23(2): 406–410.
    CrossRefPubMed
  51. Meluch AA, Greco FA, Burris HA, et al. Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network. J Clin Oncol. 2001; 19(12): 3018–3024.
    CrossRefPubMed
  52. Stadler WM, Kuzel T, Roth B, et al. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol. 1997; 15(11): 3394–3398.
    CrossRefPubMed
  53. Balar AV, Galsky MD, Rosenberg JE, et al. IMvigor210 Study Group. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. 2017; 389(10064): 67–76.
    CrossRefPubMed
  54. Balar AV, Castellano D, O'Donnell PH, et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017; 18(11): 1483–1492.
    CrossRefPubMed
  55. Bajorin DF, Dodd PM, Mazumdar M, et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol. 1999; 17(10): 3173–3181.
    CrossRefPubMed
  56. Meeks JJ, Taylor JM, Matsushita K, et al. Pathological response to neoadjuvant chemotherapy for muscle-invasive micropapillary bladder cancer. BJU Int. 2013; 111(8): E325–E330.
    CrossRefPubMed
  57. Galsky MD, Iasonos A, Mironov S, et al. Prospective trial of ifosfamide, paclitaxel, and cisplatin in patients with advanced non-transitional cell carcinoma of the urothelial tract. Urology. 2007; 69(2): 255–259.
    CrossRefPubMed
  58. Martin JW, Carballido EM, Ahmed A, et al. Squamous cell carcinoma of the urinary bladder: Systematic review of clinical characteristics and therapeutic approaches. Arab J Urol. 2016; 14(3): 183–191.
    CrossRefPubMed
  59. Tatli AM, Uysal M, Goksu SS, et al. Complete response of primary bladder adenocarcinoma with the FOLFOX4 regimen. Urol Int. 2015; 94(3): 363–365.
    CrossRefPubMed
  60. Burger M, Grossman HB, Droller M, et al. Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. Eur Urol. 2013; 64(5): 846–854.
    CrossRefPubMed
  61. Yanagihara Y, Tanji N, Miura N, et al. Modified FOLFOX6 chemotherapy in patients with metastatic urachal cancer. Chemotherapy. 2013; 59(6): 402–406.
    CrossRefPubMed
  62. Siefker-Radtke AO, Gee J, Shen Yu, et al. Multimodality management of urachal carcinoma: the M. D. Anderson Cancer Center experience. J Urol. 2003; 169(4): 1295–1298.
    CrossRefPubMed
  63. Choong NWW, Quevedo JF, Kaur JS. Small cell carcinoma of the urinary bladder. The Mayo Clinic experience. Cancer. 2005; 103(6): 1172–1178.
    CrossRefPubMed
  64. Pan Cx, Zhang H, Lara PN, et al. Small-cell carcinoma of the urinary bladder: diagnosis and management. Expert Rev Anticancer Ther. 2006; 6(12): 1707–1713.
    CrossRefPubMed
  65. Sharma P, Retz M, Siefker-Radtke A, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017; 18(3): 312–322.
    CrossRefPubMed
  66. Powles T, O'Donnell PH, Massard C, et al. Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study. JAMA Oncol. 2017; 3(9): e172411.
    CrossRefPubMed
  67. Necchi A, Joseph RW, Loriot Y, et al. Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study. Ann Oncol. 2017; 28(12): 3044–3050.
    CrossRefPubMed
  68. Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016; 387(10031): 1909–1920.
    CrossRefPubMed
  69. Powles T, Durán I, van der Heijden MS, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2018; 391(10122): 748–757.
    CrossRefPubMed
  70. Powles T, Rosenberg JE, Sonpavde GP, et al. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. N Engl J Med. 2021; 384(12): 1125–1135.
    CrossRefPubMed
  71. McConkey DJ, Choi W, Ochoa A, et al. Therapeutic opportunities in the intrinsic subtypes of muscle-invasive bladder cancer. Hematol Oncol Clin North Am. 2015; 29(2): 377–94, x.
    CrossRefPubMed
  72. McConkey DJ, Choi W, Dinney CPN. Genetic subtypes of invasive bladder cancer. Curr Opin Urol. 2015; 25(5): 449–458.
    CrossRefPubMed
  73. Bellmunt J, Théodore C, Demkov T, et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol. 2009; 27(27): 4454–4461.
    CrossRefPubMed

About cookies

Necessary cookies

Allways active

These cookies are necessary for the proper display and operation of the website. Blocking them may cause the website to malfunction.

Analytical cookies

As part of our website, we use analytical tools, such as Google Analytics, that allow us to verify website traffic. These tools may require the use of cookies.

Community cookies

These are cookies associated with the social networks we use. Accepting them will allow us to associate your visit to the site with our social media profiles.

Marketing cookies

These are cookies responsible for carrying out advertising and marketing activities - consenting to their use will allow us to target you with advertisements based on your previous activities within our website.

Copyright © 2023-2025 Via Medica Regulations Cookie policy Privacy Statement Legal Note